Arrowhead Pharmaceuticals Inc Pulmonary R&D Day Transcript
I think for the last couple of years have been tough for everybody and coming back face-to-face and talking about all this new and exciting stuff going on at Arrowhead is really, really great. So thank you for joining us.
So safe harbor. So the obligatory slide, what we're going to be talking about today includes forward-looking statements. So please refer to all the risk factors in our SEC filings.
And here are our panelists. We've got a great group to talk to you guys today about our pulmonary platform and the 2 new pulmonary products, MUC5AC and RAGE and then our newest announced program today against MMP7 for IPF. So the external panelists are Dr. Mario Castro and Dr. Matthias Salathe, both from the University of Kansas Medical Center, both are experts in the field of muco-obstructive and inflammatory pulmonary disease. So we're very lucky to have them today.
From the company myself, Chris Anzalone, our CEO; Erik Bush, our Group Vice President of Biology; James Hamilton, our Senior Vice President of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
